Treatment response assessment of breast masses on dynamic contrast-enhanced magnetic resonance scans using fuzzy c

The goal of this study was to develop an automated method to segment breast masses on dynamic contrast-enhanced DCE magnetic resonance MR scans and to evaluate its potential for estimating tumor volume on preand postchemotherapy images and tumor change in response to treatment. A radiologist experienced in interpreting breast MR scans defined a cuboid volume of interest VOI enclosing the mass in the MR volume at one time point within the sequence of DCE-MR scans. The corresponding VOIs over the entire time sequence were then automatically extracted. A new 3D VOI representing the local pharmacokinetic activities in the VOI was generated from the 4D VOI sequence by summarizing the temporal intensity enhancement curve of each voxel with its standard deviation. The method then used the fuzzy c-means FCM clustering algorithm followed by morphological filtering for initial mass segmentation. The initial segmentation was refined by the 3D level set LS method. The velocity field of the LS method was formulated in terms of the mean curvature which guaranteed the smoothness of the surface, the Sobel edge information which attracted the zero LS to the desired mass margin, and the FCM membership function which improved segmentation accuracy. The method was evaluated on 50 DCE-MR scans of 25 patients who underwent neoadjuvant chemotherapy. Each patient had preand postchemotherapy DCE-MR scans on a 1.5 T magnet. The in-plane pixel size ranged from 0.546 to 0.703 mm and the slice thickness ranged from 2.5 to 4.5 mm. The flip angle was 15°, repetition time ranged from 5.98 to 6.7 ms, and echo time ranged from 1.2 to 1.3 ms. Computer segmentation was applied to the coronal T1weighted images. For comparison, the same radiologist who marked the VOI also manually segmented the mass on each slice. The performance of the automated method was quantified using an overlap measure, defined as the ratio of the intersection of the computer and the manual segmentation volumes to the manual segmentation volume. Preand postchemotherapy masses had overlap measures of 0.81 0.13 mean s.d. and 0.71 0.22, respectively. The percentage volume reduction PVR estimated by computer and the radiologist were 55.5 43.0% mean s.d. and 57.8 51.3%, respectively. Paired Student’s t test indicated that the difference between the mean PVRs estimated by computer and the radiologist did not reach statistical significance p=0.641 . The automated mass segmentation method may have the potential to assist physicians in monitoring volume change in breast masses in response to treatment. © 2009 American Association of Physicists in Medicine. DOI: 10.1118/1.3238101

[1]  Hon J. Yu,et al.  MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy , 2007, Journal of magnetic resonance imaging : JMRI.

[2]  M D Schnall,et al.  MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. , 2001, Radiology.

[3]  Lubomir M. Hadjiiski,et al.  Characterization of mammographic masses based on level set segmentation with new image features and patient information. , 2007, Medical physics.

[4]  Andrea Schenone,et al.  A fuzzy clustering based segmentation system as support to diagnosis in medical imaging , 1999, Artif. Intell. Medicine.

[5]  C. Kuhl The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. , 2007, Radiology.

[6]  B. Asselain,et al.  Short and long‐term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial , 1999, Breast Cancer Research and Treatment.

[7]  L. Esserman,et al.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. , 2005, AJR. American journal of roentgenology.

[8]  Richard C. Pais,et al.  Evaluation of Lung MDCT Nodule Annotation Across Radiologists and Methods 1 , 2006 .

[9]  Ying Lu,et al.  MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer , 2001, Annals of Surgical Oncology.

[10]  Kecheng Liu,et al.  Shape recovery algorithms using level sets in 2-D/3-D medical imagery: a state-of-the-art review , 2002, IEEE Transactions on Information Technology in Biomedicine.

[11]  Donald S. Fussell,et al.  Interactive lesion segmentation on dynamic contrast enhanced breast MRI using a Markov model , 2006, SPIE Medical Imaging.

[12]  T. Powles,et al.  A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Giger,et al.  A fuzzy c-means (FCM)-based approach for computerized segmentation of breast lesions in dynamic contrast-enhanced MR images. , 2006, Academic radiology.

[14]  Thomas Bülow,et al.  Segmentation of suspicious lesions in dynamic contrast-enhanced breast MR images , 2007, SPIE Medical Imaging.

[15]  Mark A. Helvie,et al.  Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy , 2005, Breast Cancer Research and Treatment.

[16]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Natal A W van Riel,et al.  On the identifiability of pharmacokinetic parameters in dynamic contrast‐enhanced imaging , 2007, Magnetic resonance in medicine.

[18]  Fabian Kiessling,et al.  Determination of Pharmacokinetic Parameters in DCE MRI: Consequence of Nonlinearity Between Contrast Agent Concentration and Signal Intensity , 2006, Investigative radiology.

[19]  C. Kuhl Current status of breast MR imaging. Part 2. Clinical applications. , 2007, Radiology.

[20]  Tanja Alderliesten,et al.  Validation of Semiautomatic Measurement of the Extent of Breast Tumors Using Contrast-Enhanced Magnetic Resonance Imaging , 2007, Investigative radiology.

[21]  B. Szabó,et al.  Neural network approach to the segmentation and classification of dynamic magnetic resonance images of the breast: comparison with empiric and quantitative kinetic parameters. , 2004, Academic radiology.

[22]  H. Putter,et al.  Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902 , 2009, Breast Cancer Research and Treatment.

[23]  M. Dewhirst,et al.  Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.

[24]  T. Powles,et al.  Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Michael Brady,et al.  Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast , 2005, Medical Image Anal..

[26]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[27]  Carmel Hayes,et al.  Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.

[28]  William M. Wells,et al.  Simultaneous truth and performance level estimation (STAPLE): an algorithm for the validation of image segmentation , 2004, IEEE Transactions on Medical Imaging.

[29]  U Sinha,et al.  Segmentation strategies for breast tumors from dynamic MR images , 1996, Journal of magnetic resonance imaging : JMRI.

[30]  M. Christian,et al.  [New guidelines to evaluate the response to treatment in solid tumors]. , 2000, Bulletin du cancer.

[31]  Kelly K. Hunt,et al.  A prospective trial of preoperative chemotherapy in resectable breast cancer: Predictors of breast-conservation therapy feasibility , 2002, Annals of Surgical Oncology.

[32]  Wendy B DeMartini,et al.  Breast MR imaging: computer-aided evaluation program for discriminating benign from malignant lesions. , 2007, Radiology.